secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628280-25-038873
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q2 revenue $113.0M (+15% YoY), net income $1.3M; raises FY 2025 guidance
--------------------------------------------------------------------------------

- Revenue $113.0M vs $98.0M YoY; GAAP net income $1.3M ($0.03 EPS) vs net loss $(2.1M) prior year.
- Non-GAAP net income $10.7M ($0.24 EPS) vs $2.9M ($0.07) YoY; adjusted EBITDA $24.8M (+33%).
- On-X +24%, stent grafts +24%, BioGlue +4%, Preservation +3% constant currency growth.
- FY 2025 guidance raised: constant currency growth now 12-14%; reported revenue $435-443M.
- Retired $99.5M of convertible notes; FDA IDE approved for Arcevo LSA pivotal trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000162828025038873/0001628280-25-038873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000162828025038873/aort-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer